Cargando…
Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy
Immunotherapy has demonstrated great clinical success in the field of oncology in comparison with conventional cancer therapy. However, cancer immunotherapy still encounters major challenges that limit its efficacy against different types of cancers and the patients show minimal immune response to t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497653/ https://www.ncbi.nlm.nih.gov/pubmed/36159668 http://dx.doi.org/10.3389/fbioe.2022.1010724 |
_version_ | 1784794559115427840 |
---|---|
author | Zhao, Bonan Li, Xiang Kong, Ying Wang, Wenbo Wen, Tingting Zhang, Yanru Deng, Zhiyong Chen, Yafang Zheng, Xian |
author_facet | Zhao, Bonan Li, Xiang Kong, Ying Wang, Wenbo Wen, Tingting Zhang, Yanru Deng, Zhiyong Chen, Yafang Zheng, Xian |
author_sort | Zhao, Bonan |
collection | PubMed |
description | Immunotherapy has demonstrated great clinical success in the field of oncology in comparison with conventional cancer therapy. However, cancer immunotherapy still encounters major challenges that limit its efficacy against different types of cancers and the patients show minimal immune response to the immunotherapy. To overcome these limitations, combinatorial approaches with other therapeutics have been applied in the clinic. Simultaneously, nano-drug delivery system has played an important role in increasing the antitumor efficacy of various treatments and has been increasingly utilized for synergistic immunotherapy to further enhance the immunogenicity of the tumors. Specifically, they can promote the infiltration of immune cells within the tumors and create an environment that is more sensitive to immunotherapy, particularly in solid tumors, by accelerating tumor accumulation and permeability. Herein, this progress report provides a brief overview of the development of nano-drug delivery systems, classification of combinatory cancer immunotherapy and recent progress in tumor immune synergistic therapy in the application of nano-drug delivery systems. |
format | Online Article Text |
id | pubmed-9497653 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94976532022-09-23 Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy Zhao, Bonan Li, Xiang Kong, Ying Wang, Wenbo Wen, Tingting Zhang, Yanru Deng, Zhiyong Chen, Yafang Zheng, Xian Front Bioeng Biotechnol Bioengineering and Biotechnology Immunotherapy has demonstrated great clinical success in the field of oncology in comparison with conventional cancer therapy. However, cancer immunotherapy still encounters major challenges that limit its efficacy against different types of cancers and the patients show minimal immune response to the immunotherapy. To overcome these limitations, combinatorial approaches with other therapeutics have been applied in the clinic. Simultaneously, nano-drug delivery system has played an important role in increasing the antitumor efficacy of various treatments and has been increasingly utilized for synergistic immunotherapy to further enhance the immunogenicity of the tumors. Specifically, they can promote the infiltration of immune cells within the tumors and create an environment that is more sensitive to immunotherapy, particularly in solid tumors, by accelerating tumor accumulation and permeability. Herein, this progress report provides a brief overview of the development of nano-drug delivery systems, classification of combinatory cancer immunotherapy and recent progress in tumor immune synergistic therapy in the application of nano-drug delivery systems. Frontiers Media S.A. 2022-09-08 /pmc/articles/PMC9497653/ /pubmed/36159668 http://dx.doi.org/10.3389/fbioe.2022.1010724 Text en Copyright © 2022 Zhao, Li, Kong, Wang, Wen, Zhang, Deng, Chen and Zheng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Zhao, Bonan Li, Xiang Kong, Ying Wang, Wenbo Wen, Tingting Zhang, Yanru Deng, Zhiyong Chen, Yafang Zheng, Xian Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy |
title | Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy |
title_full | Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy |
title_fullStr | Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy |
title_full_unstemmed | Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy |
title_short | Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy |
title_sort | recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497653/ https://www.ncbi.nlm.nih.gov/pubmed/36159668 http://dx.doi.org/10.3389/fbioe.2022.1010724 |
work_keys_str_mv | AT zhaobonan recentadvancesinnanodrugdeliverysystemsforsynergisticantitumorimmunotherapy AT lixiang recentadvancesinnanodrugdeliverysystemsforsynergisticantitumorimmunotherapy AT kongying recentadvancesinnanodrugdeliverysystemsforsynergisticantitumorimmunotherapy AT wangwenbo recentadvancesinnanodrugdeliverysystemsforsynergisticantitumorimmunotherapy AT wentingting recentadvancesinnanodrugdeliverysystemsforsynergisticantitumorimmunotherapy AT zhangyanru recentadvancesinnanodrugdeliverysystemsforsynergisticantitumorimmunotherapy AT dengzhiyong recentadvancesinnanodrugdeliverysystemsforsynergisticantitumorimmunotherapy AT chenyafang recentadvancesinnanodrugdeliverysystemsforsynergisticantitumorimmunotherapy AT zhengxian recentadvancesinnanodrugdeliverysystemsforsynergisticantitumorimmunotherapy |